Skip to main content

Advertisement

Log in

Characterization of novel L-asparaginases having clinically safe profiles from bacteria inhabiting the hemolymph of the crab, Scylla serrata (Forskål, 1775)

  • Original Article
  • Published:
Folia Microbiologica Aims and scope Submit manuscript

Abstract

L-asparaginase (ASNase) is the principal chemotherapeutic agent against different blood cancers. The risks associated with current clinical preparations demand screening for novel ASNases. Accordingly, the study was conducted to shortlist ASNases having clinically safer profiles from a novel niche, namely, microbes in the gut and hemolymph of apparently healthy Scylla serrata. A four-step strategic approach incorporating the essential requirements for clinically safer profiles was followed. The initial step through plate assay showed five (9.61%) potential ASNase producers. The relative prevalence of ASNase producers was higher in hemolymph (13.33%) than gut (4.5%). The positive isolates were identified as Priestia aryabhattai, Priestia megaterium, Bacillus altitudinis, Shewanella decolorationis, and Chryseomicrobium amylolyticum. Quantitative profiles revealed high ASNase production (114.29 to 287.36 U/mL) without any optimization, with an added advantage of the extracellular production. The second step for substrate specificity studies revealed the absence of L-glutaminase and urease activities in ASNases from C. amylolyticum and P. megaterium, the most desirable properties for safe clinical applications. This is the first report of glutaminase and urease-free ASNase from these two bacteria. The third step ensured type II nature of selected ASNases, the targeted form in clinical applications. The fourth step confirmed the activity and stability in human physiological conditions. Altogether, the results revealed two potential ASNases with clinically compatible profiles.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

Data availability

The authors confirm that the data supporting the findings of this study are available within the article [and/or] its supplementary materials.

Code availability

The sequence data that generated out of the study are submitted in GenBank, NCBI and got assigned with accession codes (MZ918942, MZ916697, MZ914699, MZ914692, and MZ707763).

References

Download references

Acknowledgements

The authors are grateful to the Head, Marine Biotechnology Division, and the Director, ICAR-Central Marine Fisheries Research Institute, Kochi for providing the necessary facilities to carry out the present investigation. APV acknowledges CSIR-UGC for the research fellowship.

Funding

This work was supported by the KCSTEC funded project “Investigation for L-Asparaginase Free of Clinical Toxicity from Microbial Associations of Marine Crabs” (No. 441/2020/KSCSTE), and ICAR-CMFRI funded project “Health Management in selected finfish and shellfish & bio-prospecting from marine resources” (MBT/HLT/23).

Author information

Authors and Affiliations

Authors

Contributions

LVP executed the experimental design, combined the observations, and wrote the manuscript. TGS conceived of the presented idea, supervised the project, and facilitated the experiments. RKJ provided critical feedback and helped in the dissection and hemolymph collection from the crabs. AVN and APV and KTG provided technical support to carry out experiments. NKS helped in procuring the fund and supervising the project.

Corresponding author

Correspondence to T. G. Sumithra.

Ethics declarations

Ethics approval

All crabs in the present study were handled according to the recommended EU Directive 2010/63/EU for animal experiments and the protocols were approved by ICAR-CMFRI, Kochi-18, India.

Consent to participate

Not applicable.

Consent for publication

The manuscript has been read and approved for publication by all listed authors.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Key Points

• First report on asparaginase from S. decolorationis and C. amylolyticum

• Asparaginases from C. amylolyticum and P. megaterium have clinically safe profiles

• Points out a novel niche for the future asparaginase research

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Lailaja, V.P., Sumithra, T.G., Reshma, K.J. et al. Characterization of novel L-asparaginases having clinically safe profiles from bacteria inhabiting the hemolymph of the crab, Scylla serrata (Forskål, 1775). Folia Microbiol 67, 491–505 (2022). https://doi.org/10.1007/s12223-022-00952-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12223-022-00952-x

Navigation